Apolonia Witecka

Dr. Apolonia Witecka

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2021 in Life
Verified
Journal Article
Open access
PDF file
AWApolonia Witecka
Apolonia Witecka
SKSebastian Kwiatkowski
Sebastian Kwiatkowski
TITakao Ishikawa
Takao Ishikawa
JDJakub Drożak
Jakub Drożak
SETD3 has been recently identified as a long sought, actin specific histidine methyltransferase that catalyzes the Nτ-methylation reaction of histidine 73 (H73) residue in human actin or its equivalent in other metazoans. Its homologs are widespread among multicellular eukaryotes and expressed in most mammalian tissues. SETD3 consists of a catalytic SET domain responsible for transferring the methyl group from S-adenosyl-L-methionine (AdoMet) to a protein substrate and a RuBisCO LSMT domain that recognizes and binds the methyl-accepting protein(s). The enzyme was initially identified as a methyltransferase that catalyzes the modification of histone H3 at K4 and K36 residues, but later studies revealed that the only bona fide substrate of SETD3 is H73, in the actin protein. The methylation of actin at H73 contributes to maintaining cytoskeleton integrity, which remains the only well characterized biological effect of SETD3. However, the discovery of numerous novel methyltransferase interactors suggests that SETD3 may regulate various biological processes, including cell cycle and apoptosis, carcinogenesis, response to hypoxic conditions, and enterovirus pathogenesis. This review summarizes the current advances in research on the SETD3 protein, its biological importance, and role in various diseases.

27 June 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AWApolonia Witecka
Apolonia Witecka
VKVarvara Kazak
Varvara Kazak
SKSebastian Kwiatkowski
Sebastian Kwiatkowski
AKAnna Kiersztan
Anna Kiersztan
AJAdam K. Jagielski
Adam K. Jagielski
JDJakub Drożak
Jakub Drożak
L-Fucose (6-deoxy-L-galactose), a monosaccharide abundant in glycolipids and glycoproteins produced by mammalian cells, has been extensively studied for its role in intracellular biosynthesis and recycling of GDP-L-fucose for fucosylation. However, in certain mammalian species, L-fucose is efficiently broken down to pyruvate and lactate in a poorly understood metabolic pathway. In the 1970s, L-fucose dehydrogenase, an enzyme responsible for the initial step of this pathway, was partially purified from pig and rabbit livers and characterized biochemically. However, its molecular identity remained elusive until recently. This study reports the purification, identification, and biochemical characterization of the mammalian L-fucose dehydrogenase. The enzyme was purified from rabbit liver approximately 340-fold. Mass spectrometry analysis of the purified protein preparation identified mammalian hydroxysteroid 17-β dehydrogenase 14 (HSD17B14) as the sole candidate enzyme. Rabbit and human HSD17B14 were expressed in HEK293T and Escherichia coli, respectively, purified, and demonstrated to catalyze the oxidation of L-fucose to L-fucono-1,5-lactone, as confirmed by mass spectrometry and NMR analysis. Substrate specificity studies revealed that L-fucose is the preferred substrate for both enzymes. The human enzyme exhibited a catalytic efficiency for L-fucose that was 359-fold higher than its efficiency for estradiol. Additionally, recombinant rat HSD17B14 exhibited negligible activity towards L-fucose, consistent with the absence of L-fucose metabolism in this species. The identification of the gene-encoding mammalian L-fucose dehydrogenase provides novel insights into the substrate specificity of enzymes belonging to the 17-β-hydroxysteroid dehydrogenase family. This discovery also paves the way for unraveling the physiological functions of the L-fucose degradation pathway, which remains enigmatic.

4 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AWApolonia Witecka
Apolonia Witecka
JKJulia Zuzanna Kamińska
Julia Zuzanna Kamińska
KŚKlaudia Ślusarczyk
Klaudia Ślusarczyk
JPJan Jakub Piętka
Jan Jakub Piętka
MWMikołaj Witczak
Mikołaj Witczak
JDJakub Drożak
Jakub Drożak
Orphan enzymes are recognized and classified enzymatic activities that lack associated amino acid sequences. Since the term was coined in the mid-2000s, the proportion of orphan enzymes has substantially decreased; however, it is estimated that at least ≈900 enzymatic activities remain devoid of molecular identity to date. The putative mammalian metabolic pathway for L-fucose degradation represents a system that long consisted exclusively of orphan enzymes, with only a few recently “deorphaned” and biochemically characterized. L-Fucose is a unique monosaccharide frequently found in various glycolipids and glycoproteins synthesized by mammalian cells, such as the ABO blood group antigens in humans. While the importance of the biosynthetic pathways for its active form (GDP-L-fucose) is well established in diverse biological processes, the enzymology and physiological role of L-fucose catabolism remain largely enigmatic. In this review, we summarize the current knowledge regarding the enzymological and physiological aspects of L-fucose catabolism in mammals.